In vitro activities of faropenem, ertapenem, imipenem and meropenem against Borrelia burgdorferi s.l.

Int J Antimicrob Agents

Institute of Medical Microbiology & Infection Control, University Hospital of Frankfurt, Paul-Ehrlich Str. 40, D-60596 Frankfurt/Main, Germany.

Published: July 2007

Little is known about the in vitro activity of penems and carbapenems against the spirochete Borrelia burgdorferi. Here, faropenem, ertapenem, imipenem and meropenem as well as the third-generation cephalosporin ceftriaxone and tobramycin were tested in vitro against 11 isolates of the B. burgdorferi sensu lato complex. On a microg/mL basis, ertapenem was the most potent carbapenem (minimal inhibitory concentration (MIC) range: 0.015-0.125 microg/mL), with in vitro activity comparable with that of ceftriaxone against Borrelia. These findings are supported by the results of time-kill experiments in a Borrelia afzelii skin isolate, demonstrating a >3 log10 unit (99.9%) reduction of the inoculum after 96 h of exposure to either drug at a concentration of three log2 unit dilutions above the respective MIC.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ijantimicag.2007.03.008DOI Listing

Publication Analysis

Top Keywords

faropenem ertapenem
8
ertapenem imipenem
8
imipenem meropenem
8
borrelia burgdorferi
8
vitro activity
8
vitro
4
vitro activities
4
activities faropenem
4
borrelia
4
meropenem borrelia
4

Similar Publications

Objectives: To analyse carbapenemases in Proteus mirabilis and assess the performance of carbapenemase detection assays.

Methods: Eighty-one clinical P. mirabilis isolates with high-level resistance at least to ampicillin (>32 mg/L) or previous detection of carbapenemases were selected and investigated by three susceptibility testing methods (microdilution, automated susceptibility testing, and disk diffusion), six phenotypic carbapenemase assays (CARBA NP, modified carbapenemase inactivation method [CIM], modified zinc-supplemented CIM, simplified CIM, faropenem, and carbapenem-containing agar), two immunochromatographic assays, and whole-genome sequencing.

View Article and Find Full Text PDF

Are the Newer Carbapenems of Any Value against Tuberculosis.

Antibiotics (Basel)

August 2022

Department of Infectious Diseases, Faculty of Medicine, Imperial College, London W12 0NN, UK.

Our aim was to assess whether newer carbapenems with a better administration profile than meropenem (ertapenem, faropenem and tebipenem) were more effective against including M/XDRTB and determine if there was a synergistic/antagonistic effect with amoxicillin or clavulanate (inhibitor of beta-lactamases that MTB possesses) in vitro. Whilst meropenem is given three times a day intravenously, ertapenem, though given parenterally, is given once a day, faropenem and tebipenem are given orally. Eighty-two clinical drug-sensitive and -resistant MTB strains and a laboratory strain, H37Rv, were assessed by a microdilution methodology against ertapenem, faropenem, tebipenem and meropenem with and without amoxicillin or clavulanic acid.

View Article and Find Full Text PDF

The role of Acinetobacter baumannii CarO outer membrane protein in carbapenems influx.

Res Microbiol

July 2022

Artvin Coruh University, Vocational School of Health Services, Medical Laboratory Techniques, Artvin, Turkey. Electronic address:

The gram-negative strain Acinetobacter baumannii is a cocobacillus, non-motile and aerobic organism that is often found in nosocomial infections. Many institutions worldwide such as WHO are grappling with antibiotic resistance A. baumannii.

View Article and Find Full Text PDF

Carbapenems play an important role in the management of bacterial infections. Meropenem, imipenem, ertapenem, and faropenem are carbapenems with the broadest antibacterial spectrum and strong antibacterial activity. Faropenem is a novel oral carbapenem with an advantage over other parenteral carbapenems in the series.

View Article and Find Full Text PDF

Widespread bacterial resistance to carbapenem antibiotics is an increasing global health concern. Resistance has emerged due to carbapenem-hydrolyzing enzymes, including metallo-β-lactamases (MβLs), but despite their prevalence and clinical importance, MβL mechanisms are still not fully understood. Carbapenem hydrolysis by MβLs can yield alternative product tautomers with the potential to access different binding modes.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!